Expression in human prostate of drug- and carcinogen-metabolizing enzymes: association with prostate cancer risk
1998

Enzymes and Prostate Cancer Risk

Sample size: 254 publication Evidence: moderate

Author Information

Author(s): JAG Agundez, C Martinez, M Olivera, L Gallardo, JM Ladero, C Rosado, J Prados, J Rodriguez-Molina, L Resel, J Benitez

Primary Institution: University of Extremadura

Hypothesis

The study investigates the relationship between polymorphisms of drug- and carcinogen-metabolizing enzymes and prostate cancer risk.

Conclusion

The study found no significant association between the polymorphisms of the NAT2 and CYP2D6 enzymes and prostate cancer risk.

Supporting Evidence

  • Enzyme activities corresponding to NAT2, CYP2D6, and CYP3A were present in human prostate tissue.
  • High interindividual variability in enzyme activity may influence cancer susceptibility.
  • No statistically significant differences in enzyme polymorphisms were found between cancer patients and healthy controls.

Takeaway

This study looked at how certain genes that help break down drugs and cancer-causing substances might affect the risk of getting prostate cancer, but it found no clear link.

Methodology

The study analyzed DNA from 94 prostate cancer patients and 160 healthy controls to assess enzyme activity and genetic polymorphisms.

Limitations

The study's sample size may limit the ability to detect significant associations.

Participant Demographics

Unrelated white Spanish men, aged 18-95, with prostate cancer and healthy controls.

Statistical Information

Confidence Interval

95% CI = 0.7-1.9

Statistical Significance

p>0.05

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication